From: Kylene Kehn-Hall
Sent: Wednesday, February 19, 2020 6:55 AM
To: Kimberly L Harris <[log in to unmask]>
Subject: FW: Postdoctoral Fellowship Opportunity at FDA
Can you send this to our Biosciences PhD students?
From: Kathryn E Agoston
Sent: Tuesday, February 18, 2020 9:26 PM
To: Kylene Kehn-Hall <[log in to unmask]>
Subject: Postdoctoral Fellowship Opportunity at FDA
This postdoctoral opportunity came across my desk, and I wondered if you have any new/recent PhDs or postdocs out your way who might be a good fit: https://www.zintellect.com/Opportunity/Details/FDA-CBER-2020-0009
FDA Postdoctoral Research Opportunity in Live Attenuated Viral Vectors
U.S. Food and Drug Administration (FDA)
How to Apply
A complete application consists of:
All documents must be in English or include an official English translation.
If you have questions, send an email to [log in to unmask]. Please include the reference code for this opportunity in your email.
3/16/2020 3:00:00 PM Eastern Time Zone
*Applications will be reviewed on a rolling-basis.
A research opportunity is available in the Division of Viral Products (DVP), Office of Vaccines Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The goal of this project is to enhance vaccine potency by expressing a desired vaccine antigen in a live viral vector. The vector is the rubella vaccine strain, which has demonstrated its safety and potency in millions of children each year. During this project, we will insert a foreign gene into the structural insertion site of the rubella virus genome. As a result, every time the rubella vector infects a cell it expresses both its own proteins and the new vaccine insert. This combines the safety and potency of the vector with the antigenicity of the vaccine insert.
For example, the insert can be SIV gag protein. Rubella can accommodate the entire SIV gag protein p27. This gene is stably expressed for more than 10 passages in cell culture. It is also expressed when the vector grows in vivo. This results in strong antibody titers and T cell immunity against SIV gag that are comparable to SIV infection. The result may be immune protection against SIV infection.
Similarly, the insert can be malaria CSP protein. Antibodies specific for CSP can protect against malaria infection. One quarter of the world's population are at risk of malaria, and there is no vaccine. The rubella/CSP vectors are designed to establish sufficient immunity in young children to protect against malarial infection and reduce lethal disease in this age group.
Recently, we have found that certain host cell proteins can be expressed by rubella. If we make antibodies against certain cell proteins on the surface of lymphocytes, we can knock out the function of an entire cell subset. For example, antibodies to CD20, CD4, or CD8 could wipe out the effector functions of B cells, helper T cells, or cytolytic T cells if given separately. But, if given together, they could modulate the function of all lymphocytes. We have succeeded in expressing CD20, and this may be a gateway construct for the others. This includes both type I and type II membrane proteins.
Under the guidance of a mentor, the participant will be involved in the following training activities:
CBER has animal facilities that provide unique access to macaques for immunization studies of vaccine structure and immune function.
Learning objectives for this project include: vaccine design, improving skills in molecular biology, analyzing vector growth and protein expression, and performing in vitro assays that predict immune function in vivo.
Over the course of this opportunity, we are looking for growth in planning experiments and analyzing results. This will include opportunities to solve problems in protein expression and stability. The selected participant will also participate in choosing new target antigens for greater vaccine potency.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should have received a doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
Kay Ágoston, PhD
Director of Graduate Fellowships
Office of the Provost
George Mason University